ArticleJournal of hematology & oncology2025

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

Daruka Mahadevan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.